Geron Co. (NASDAQ:GERN – Get Rating) has been assigned a consensus recommendation of “Hold” from the six brokerages that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The average […]
Geron Co. (NASDAQ:GERN – Get Rating) has received an average rating of “Hold” from the six brokerages that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year […]
Geron Co. (NASDAQ:GERN – Get Rating) – Research analysts at B. Riley decreased their FY2026 earnings per share estimates for Geron in a note issued to investors on Friday, May 12th. B. Riley analyst K. Patel now expects that the biopharmaceutical company will earn $0.07 per share for the year, down from their previous estimate […]
Geron Co. (NASDAQ:GERN – Get Rating) – Equities research analysts at Wedbush dropped their FY2027 earnings estimates for shares of Geron in a report issued on Friday, May 12th. Wedbush analyst R. Driscoll now forecasts that the biopharmaceutical company will post earnings of $0.59 per share for the year, down from their previous estimate of […]
Geron Co. (NASDAQ:GERN – Get Rating) was the target of a significant growth in short interest in April. As of April 30th, there was short interest totalling 23,610,000 shares, a growth of 5.3% from the April 15th total of 22,420,000 shares. Based on an average daily trading volume, of 5,430,000 shares, the days-to-cover ratio is […]